Abstract
B cells play a central role in the pathogenesis of SLE. Not only do they make autoantibodies, but they can provide immunoregulatory controls of T cells, dendritic cells, and other B cells, in part through cytokine production. The availability of a chimeric monoclonal antibody that targets B cells has made it possible to treat SLE by B-cell depletion. Rituximab binds to the B-cell specific antigen CD20, and depletes B cells from the peripheral blood and lymphoid tissues. A growing number of anecdotal series and case reports suggest that rituximab may provide clinical benefit in SLE with acceptable toxicity, although the variability in responses of individual patients is not yet fully understood. Two large ongoing randomized controlled trials will determine the efficacy of rituximab in SLE, both renal and extra-renal, and will inform us better about the biology of the B cell in this disease and the effects of B-cell depletion.
Keywords: SLE, B cells, rituximab, CD20, chimeric monoclonal antibody
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20)
Volume: 6 Issue: 4
Author(s): Robert Eisenberg
Affiliation:
Keywords: SLE, B cells, rituximab, CD20, chimeric monoclonal antibody
Abstract: B cells play a central role in the pathogenesis of SLE. Not only do they make autoantibodies, but they can provide immunoregulatory controls of T cells, dendritic cells, and other B cells, in part through cytokine production. The availability of a chimeric monoclonal antibody that targets B cells has made it possible to treat SLE by B-cell depletion. Rituximab binds to the B-cell specific antigen CD20, and depletes B cells from the peripheral blood and lymphoid tissues. A growing number of anecdotal series and case reports suggest that rituximab may provide clinical benefit in SLE with acceptable toxicity, although the variability in responses of individual patients is not yet fully understood. Two large ongoing randomized controlled trials will determine the efficacy of rituximab in SLE, both renal and extra-renal, and will inform us better about the biology of the B cell in this disease and the effects of B-cell depletion.
Export Options
About this article
Cite this article as:
Eisenberg Robert, Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20), Endocrine, Metabolic & Immune Disorders - Drug Targets 2006; 6 (4) . https://dx.doi.org/10.2174/187153006779025757
DOI https://dx.doi.org/10.2174/187153006779025757 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protease-Activated Receptor-2 Antagonists and Agonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Vaccination Against High Blood Pressure
Current Pharmaceutical Design Bradykinin Antagonists as Anti-Cancer Agents
Current Pharmaceutical Design Endothelin-Converting Enzyme Inhibitors
Current Enzyme Inhibition Cytotoxic Potential of Phenothiazines
Current Drug Targets Monitoring the Pharmacokinetics of Pyridinium Aldoximes in the Body
Mini-Reviews in Medicinal Chemistry Chromogranin A as a Calcium-Binding Precursor for a Multitude of Regulatory Peptides for the Immune, Endocrine and Metabolic Systems
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Bcl-2 Proteins: Targets and Tools for Chemosensitisation of Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents Peptidergic Regulation of Pheochromocytoma
Current Pharmacogenomics Tenofovir-Related Nephropathies in HIV-Infected Patients
Current Vascular Pharmacology Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry COX-Inhibiting Nitric Oxide Donors (CINODs): Potential Benefits on Cardiovascular and Renal Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Lipases Aided Esterification of (2,2-Dimethyl-1,3-dioxolan-4-yl)methanol
Letters in Organic Chemistry Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science Critical Congenital Heart Disease in Neonates: A Review Article
Current Pediatric Reviews Ranolazine : Effects on Ischemic Heart
Recent Patents on Cardiovascular Drug Discovery The Validity of Chemical Analytical Methods by the Example of the Heparin Product Recall
Current Pharmaceutical Analysis Life Threatening and Fatal Contrast Media Reactions: Pathomechanisms, Diagnosis, Prevention and Drug Management
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Digital Ulcers in Systemic Sclerosis – How to Manage in 2013?
Current Rheumatology Reviews The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets